 The stock price of Intellia Therapeutics, a biotechnology company developing treatments using a CRISPR gene-editing system, has seen a significant 31 fall in a month while it is down 34 over the last week. This can be attributed to the U.S. Patents Trademark Office ruling invalidating a key. 